PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.865 EUR | -0.52% |
|
-4.34% | -37.72% |
| Sales 2024 * | 1.05M 1.13M | Sales 2025 * | 1.6M 1.73M | Capitalization | 17.4M 18.8M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 1M 1.08M | EV / Sales 2024 * | 17 x |
| Net Debt 2024 * | 450K 486K | Net Debt 2025 * | 10.55M 11.39M | EV / Sales 2025 * | 17.5 x |
| P/E ratio 2024 * |
-2.03
x | P/E ratio 2025 * |
-3.02
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 week | -4.34% | ||
| Current month | -4.34% | ||
| 1 month | -1.21% | ||
| 3 months | -3.54% | ||
| 6 months | -36.12% | ||
| Current year | -37.72% |
1 week
2.87
3.04
1 month
2.873.08
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 2.865 | -0.52% | 2,202 |
| 24-06-06 | 2.88 | -2.54% | 7,161 |
| 24-06-05 | 2.955 | -0.17% | 9,161 |
| 24-06-04 | 2.96 | 0.00% | 1,494 |
| 24-06-03 | 2.96 | -1.17% | 2,249 |
Real-time Euronext Paris, June 07, 2024 at 11:35 am EDT
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-06-27
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.865
EUR
Average target price
7.05
EUR
Spread / Average Target
+146.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
